- What is the platform?
- Women's Health Foundry is a national translation platform for women's health ventures: selection, milestone-based de-risking, gate reviews, scale-up support, and partner and capital pathways. It moves selected innovations toward investable, adoptable outcomes.
- Who is it for?
- Primarily researcher-led teams and founders building therapeutics, diagnostics, devices, biomarkers, and digital tools where women's health outcomes are central. Partners include academic institutions, clinical services, consumers and advocates, industry, and investors, each with a distinct role.
- Is funding open?
- The platform is in development. Register interest to receive updates when intake processes and governance are confirmed.
- Is this Proto Axiom?
- Proto Axiom is the builder-operator behind the platform. Women's Health Foundry is the public program identity for institution-facing translation work. See the About page for details.
- What does "register interest" mean?
- A way to share your role, contact details, and optional context so we can prioritise outreach as the program launches. It is not a formal application or funding commitment.
- Is the platform virtual or physical?
- National infrastructure: coordination, milestones, and partner pathways are not tied to a single building. In-person engagement happens where governance and program design require it, for example clinical sites or hosted sessions.
- What happens after I register interest — and how long does it take?
- Register interest is not a scored application. We use your details to understand demand and to plan outreach as program settings and governance are confirmed. You should not expect a fixed timeline; updates arrive when there is something concrete to share (for example, when intake processes open). Nothing in the form is an offer, admission, or funding commitment.
- How does this relate to existing accelerators or incubators?
- The platform is designed as specialist translation infrastructure for women's health — milestone-based de-risking, gate reviews, and evidence-aligned support — not a generic accelerator. It can complement university programs, hospital innovation hubs, and national schemes where timelines and governance fit; it is not a substitute for your institution's own requirements or for independent legal and clinical advice.
- Are international applicants or teams eligible?
- The program is being developed with Australian national scope and institutions in mind. International interest helps us understand demand; final eligibility, including for teams based overseas or with mixed jurisdictions, will be published when intake settings are confirmed.
- What does "non-dilutive" funding mean in practice?
- Non-dilutive funding is capital that does not take equity in your company (unlike most venture investment). In practice it still comes with milestones, reporting, and use-of-funds expectations. It is not "free money" — it is often tied to de-risking steps and public-policy intent. Exact instruments will depend on program design when settings are finalised.
- How does consumer and community involvement work?
- Women's health innovation is stronger when people with lived experience help shape priorities, evidence design, and adoption assumptions — aligned with governance and ethics requirements. The platform is being designed so consumer and community voice can be embedded in selection and program logic where appropriate, not treated as an afterthought. Details will follow as governance is confirmed.
Questions
Frequently asked questions
Straight answers about scope, funding status, Proto Axiom, and what register interest does — subject to the site disclaimer.